A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis
Sponsor: Botanix Pharmaceuticals
This PHASE2 trial investigates Hyperhidrosis and is currently completed. Botanix Pharmaceuticals leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Completed PHASE2
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Botanix Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.